Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03308942
Recruitment Status : Active, not recruiting
First Posted : October 13, 2017
Last Update Posted : January 14, 2020
Myriad Genetics, Inc.
NeoGenomics Laboratories
Resolution Bioscience
Syneos Health
Almac Group
Information provided by (Responsible Party):
Tesaro, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022